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Karolinska Institute, and 2Division of Surgery, Karolinska Institute, Danderyd Hospital, Stockholm, SwedenObjective. Oxidative stress and inflammation in the vessel wall may play important roles in the development of restenosis
after angioplasty. Reactive oxygen species have been suggested to mediate the proliferative phenotype in smooth muscle cells.
The role of the redox-active proteins, thioredoxin and glutaredoxin, after angioplasty in patients with peripheral arterial
disease has never been assessed before. Circulating thioredoxin impairs the chemotactic response to local sites of
inflammation and administration of human recombinant Trx has been shown to attenuate ischemic reperfusion injury.
Methods and results. Patients with peripheral arterial disease undergoing angioplasty were included in this observational
study. Plasma levels of thioredoxin and glutaredoxin were analysed before and 1, 4 and 24 h, and 1 week after angioplasty.
Plasma levels of thioredoxin were significantly elevated 4 h after angioplasty [2.3 ng/ml (0.5–14), pZ0.02] and returned to
baseline within 24 h [1.1 ng/ml (0.5–3.1), pZ0.02]. There may also exist an association between patients with elevated
levels of thioredoxin after angioplasty and decreased rate of restenosis at follow-up angiography after 6 months. There were
no changes in plasma levels of glutaredoxin after angioplasty.
Conclusion. These findings provide a new insight to the role of thioredoxin in the complex process of vascular injury and
restenosis in patients with peripheral arterial disease, suggesting thioredoxin both as a marker of oxidative stress and as a
therapeutic agent.Keywords: Thioredoxin; Glutaredoxin; Oxidative stress; Angioplasty; Restenosis.Introduction
Thrombosis and restenosis remain frequent compli-
cations after percutaneous transluminal angioplasty
(PTA) in peripheral arterial disease. Vascular smooth
muscle cell (VSMC) proliferation, increased volume of
extracellular matrix, thrombosis, and vascular remo-
delling all contribute to the pathogenesis of rest-
enosis.1 There are accumulating evidence indicating
that oxidative stress in the vessel wall is involved in
atherosclerosis.2 In particular, oxidative stress occurs
after balloon angioplasty and there is evidence for
redox processes as mediators of vascular repair and
contributors to development of restenosis. Reactive
oxygen species (ROS) can induce endothelial dysfunc-
tion and macrophage activation, resulting in the
release of cytokines and growth factors that stimulate
matrix remodelling and SMC proliferation.3ing author. Carl-Magnus Wahlgren, MD, Department
urgery, Karolinska University Hospital, 171 77 Stock-
n.
: carl.wahlgren@karolinska.se
0281+ 06 $35.00/0 q 2004 Elsevier Ltd. All rights reserHuman thioredoxin (Trx) is a 12 kDa protein
catalysing oxido-reductase reactions. Trx exerts its
effects by this mechanism in numerous different
cellular systems. Intracellular Trx is a general anti-
oxidant and activates several transcription factors like
NF-kb and AP-1.4 In the extracellular milieu Trx is a
co-cytokine and chemokine for monocytes, T cells and
polymorphonuclear neutrophils. Plasma levels of Trx
are changed in both neoplastic diseases as well as in
inflammatory diseases.5 Increased plasma levels of Trx
are a sensitive indicator of oxidative stress.6,7 Glutar-
edoxin (Grx) was originally discovered as the second
hydrogen donor for ribonucleotide reductase in
Escherichia coli lacking Trx.8 Grx is distinguished
from Trx by its ability to be reduced by glutathione
(GSH). In addition, it is associated with apoptosis and
to control DNA binding of transcription factors.9–11
Treatment with a variety of antioxidants has
reduced neointimal proliferation and promoted vessel
remodelling in animal models.12 In balloon-injured rat
carotid arteries, Trx expression was increased in the
neointimal regenerating endothelial cells.13 Enhanced
Trx and Grx expression throughout the vessel wall, butEur J Vasc Endovasc Surg 29, 281–286 (2005)
doi:10.1016/j.ejvs.2004.12.020, available online at http://www.sciencedirect.com onved.
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described in human coronary artery specimens.13
A protective effect of Trx against ROS-induced
cellular damage has been demonstrated in vivo.14 Also
circulating Trx can block neutrophil extravasation into
inflammatory sites.15 Intravenous administration of
human recombinant Trx has been shown to attenuate
ischemia-reperfusion injury in animal models.16–18
The role of Trx and Grx in peripheral arterial disease
has never been assessed before. The aim of this
prospective observational study was to evaluate the
response of Trx and Grx after PTA in patients with
peripheral arterial disease and to correlate the plasma
levels of these redox-active proteins with the occur-
rence of restenosis.Materials and MethodsSelection of patients
Nineteen consecutive patients admitted to the depart-
ment of vascular surgery for elective PTA were
enrolled in the study. Ten patients, undergoing
diagnostic angiography, were included in the study
as controls. Patient characteristics are shown in Table
1. The local ethics committee approved the study and
all patients gave written informed consent to partici-
pate. Patients undergoing angioplasty of bypass
grafts, redo procedures, or primary local thrombolysis
were excluded from the study.Table 1. Patient characteristics for both the study and control group
at baseline, including risk factors, medication, indication and
location for angioplasty
Study group Controls
Patients/limbs treated 19/19 10/0
Men 10 (53%) 6 (60%)
Age (years) 68 (54–81) 72 (55–84)
Risk factors
Hypertension 13 (68%) 6 (60%)
Diabetes mellitus 9 (47%) 1 (10%)
Renal insufficiency 1 (5%) 1 (10%)
Cardiac disease 5 (26%) 4 (40%)
Smoking 7 (37%) 5 (50%)
Medication
Aspirin 9 (47%) 7 (70%)
ACE-inhibitor 5 (26%) 4 (40%)
Beta-blocker 5 (26%) 4 (40%)
Statin 9 (47%) 5 (50%)
Indication
Intermittent claudication 18 (95%) 8 (80%)
Critical ischemia 1 (5%) 2 (20%)
Location
Common/external iliac artery 17 (89%)
Superficial femoral artery 2 (11%)
Stent 17 (89%)
Eur J Vasc Endovasc Surg Vol 29, March 2005Surgical method
PTA was performed in an angiography suite by an
interventional radiologist or a vascular surgeon. An
ipsilateral antegrade or a contralateral retrograde
percutaneous puncture of the femoral artery was
performed. All suitable lesions were treated with
balloon angioplasty. Only stenoses above 50% were
accepted. The diameter of the artery was measured
digitally after calibration. The balloon diameter was
selected to be equal or above 1 mm to that of the non-
stenosed artery. Patients received 5000 U of heparin
intraarterially before angioplasty. A balloon diameter
ranging from 5 to 9 mm was used. Inflation pressure
was 6–14 atmosphere during approximately 30 s.
Technical success was defined as PTA resulting in
less than 30% residual stenosis after dilatation.
Hemodynamic improvement was defined as an
increase in ankle/brachial index (ABI)O0.10.19 Auto-
mated vessel analysis was performed on Philips
Integris V software to assess arterial stenoses.
Stent placement was done for residual stenoses due
to elastic recoil or residual gradients exceeding 10 mm
Hg post-PTA. A highly eccentric stenosis or dissection
as a result of PTA was an indication for stent
placement. The pressure gradient across the stenosis
was measured. A peak systolic resting pressure
gradient above 10 mmHg was considered hemodyna-
mically significant. Clinical examination and ABI were
performed before and after angioplasty. Patients were
followed up with angiography after 6 months to
evaluate restenosis. Restenosis was defined as more
than 20% further lumen diameter reduction at the site
of PTA (lumen diameter reduction at 6 months minus
lumen diameter reduction post-PTA). Four patients
declined follow-up at 6 months.Definitions
Hematoma and distal embolization were classified as
minor complications. Major bleeding requiring emer-
gency surgery, thrombosis requiring local thromboly-
sis, myocardial infarction, renal failure, and
cerebrovascular accidents were considered as major
complications.
Intermittent claudication and critical ischemia were
defined according to the criteria proposed by the
Society for Vascular Surgery and International Society
for Cardiovascular Surgery (SVS/ISCVS).20 Diabetes
mellitus and hypertension was defined according to
the World Health Organisation (WHO) criteria. Car-
diac disease included patients with active class II to IV
angina pectoris according to the Canadian
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myocardial infarction, or congestive heart failure class
II to IV according to the New York Heart Association
(NYHA) classification. Renal insufficiency was defined
as a serum creatinine level of 120 mmol/l or higher.Blood samples
Venous blood was drawn from an antecubital vein
before and 1, 4, and 24 h, and 1 week after PTA into
tubes containing 0.5 ml of 0.129 M citrate (Becton
Dickinson Vacutainer Systems, Myealn Cedex,
France). In the control group, blood samples were
drawn before and 1 and 4 h after PTA. The blood
samples were centrifuged within 30 min at 2000 rpm
for 20 min. The plasma fraction was removed and
stored atK70 8C until use. Anti-thrombin, APTT, and
INR were measured by routine laboratory methods.Measurement of Trx and Grx
Trx was measured in duplicated plasma samples as
previously described.21 Briefly, a sandwich ELISAwas
conducted using a monoclonal anti-Trx antibody as
the primary antibody, ensuring no unspecific binding
to truncated Trx (Trx80).22 Subsequently, Trx standards
and plasma samples were added in duplicates and a
secondary biotinylated polyclonal goat anti-Trx anti-
body was added. Finally, alkaline phosphatase-con-
jugated streptavidin was added and the reaction was
developed by p-nitrophenyl phosphate. Absorbance
was recorded at 405 nm by a microplate reader
(Thermomax, Molecular Devices). Data were analysed
using the accompanying SOFTmax version 2.31 soft-
ware. Detection limit for the Trx sandwich ELISAwas
0.5 ng/ml. Intra-assay and inter-assay coefficients of
variation were 4.5 and 4.7%, respectively.
Plasma levels of Grx were measured in a
sandwich ELISA with a primary affinity purified
goat anti-Grx1 antibody.23 The secondary antibody
was the same as the primary but biotinylated.
Finally, alkaline phosphatase-conjugated streptavi-
din was added and the reaction was developed by p-
nitrophenyl phosphate. Absorbance was recorded, as
for Trx, at 405 nm by a microplate reader (Thermo-
max, Molecular Devices). Data were analysed using
the accompanying SOFTmax version 2.31 software.
Detection limit for the Grx sandwich ELISA was
0.2 ng/ml. Intra-assay and inter-assay coefficients of
variation were 7.3%, respectively. Hemolysis in Trx
and Grx plasma samples was negligible.Statistical analysis
The statistical significance of differences between
plasma levels of Trx or Grx at different time points
were determined by using repeated measures analysis
of variance (ANOVA). Post hoc tests were performed
with Fisher’s Protected Least Significant Difference
(PLSD). Mann–Whitney U and Wilcoxon signed rank
tests were used when appropriate. Values are
expressed as mean and ranges, unless otherwise
specified. StatView 5.0 (SAS institute Inc., Cary, NC,
USA) was used for statistical calculations.ResultsOutcome of angioplasty
The technical success after PTAwas 100%. There were
four occlusions (21%) and fifteen stenoses (79%).
Seventeen stents were placed (89%). The mean peak
systolic pressure gradient over the stenoses before
intervention was 36 (12–83) mmHg and after 12 (1–
40) mmHg (pZ0.008). Ankle-brachial index (ABI)
before intervention was 0.60 (0–1.0) and after 0.75
(0.4–1.1) (pZ0.01). After 1 month ABI was 0.75 (0–1.2)
which was still increased compared to before inter-
vention (pZ0.05). There were no minor or major
complications and there was no mortality at follow-up
after 6 months.
No low-molecular-weight heparin was given after
PTA. Nine patients were on acetyl-salicylic acid (ASA)
before PTA. Five further patients received 75 mg of
ASA post-PTA and in four patients 75 mg of Clopido-
grel was added.
The mean plasma levels of anti-thrombin, APTT,
and INR were 1.0 kE/l (0.9–1.2), 32 s (27–38), and 1.0
(0.9–1.2), respectively.Trx/Grx after angioplasty
After PTA plasma levels of Trx were elevated at 4 h
compared to baseline (pZ0.02). The levels then
decreased to baseline after 24 h (pZ0.02) and stayed
at that level after 1 week (pZ0.006) (Table 2). In
contrast, plasma levels of Grx remained unchanged
when Grx levels before and after PTAwere compared
(pZ0.60) (Table 2). There were also no changes in
plasma levels of Trx or Grx after angiography in the
control group (pZ0.39 and pZ0.17, respectively)
(Table 2). There was also no correlation between the
balloon pressure at dilatation and the release of Trx or
Grx.Eur J Vasc Endovasc Surg Vol 29, March 2005
Table 2. Plasma levels of Thioredoxin (Trx) and Glutaredoxin (Grx) before and after angioplasty (PTA) and angiography (controls) in
patients with peripheral arterial disease
Before 1 h 4 h 24 h 1 week
Trx, ng/ml (PTA) 1.1 (0.5–3.6) 1.6 (0.5–5.6) 2.3 (0.5–14)* 1.1 (0.5–3.1) 0.9 (0.5–2.2)
Trx, ng/ml (control) 5.6 (0.5–21) 2.2 (0.5–7.3) 3.9 (0.5–15) – –
Grx, ng/ml (PTA) 4.1 (0.3–12) 2.5 (0.3–9.4) 3.8 (0.3–19) 3.0 (0.3–7.4) 3.8 (0.3–14)
Grx, ng/ml (control) 16 (3.1–72) 8.3 (1.8–23) 6.1 (1.5–11) – –
Values are mean and ranges.
* pZ0.02 vs. before, pZ0.02 vs. 24 h, and pZ0.006 vs. 1 week.
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Angiography 6 months after PTA showed a mean
lumen reduction at the site of PTA of 23% (0–60%). The
mean peak systolic pressure gradient over the stenoses
was 10 (1–25%) mmHg. There were six patients (32%)
with restenosis (defined as more than 20% further
diameter reduction at the site of PTA). The mean
lumen reduction at the site of PTAwas 38% (26–60) in
the restenosis group compared to 14% (0–20%) in the
group without restenosis. We observed elevated levels
of Trx at 4 h after PTA in the group of patients without
restenosis (Table 3). The statistical significance of this
observation was rather weak (pZ0.12). There was no
such observation in the Grx group. There was no
obvious difference between the restenosis and the non-
restenosis group regarding risk factors and medi-
cation. Risk factors and medications had no significant
influence on the outcome at 6 months.Discussion
We found an increase in plasma levels of Trx 4 h after
angioplasty and levels returned to baseline after 24 h.
Several studies have shown that Trx is a sensitive
indicator of oxidative stress.6,7 Oxidative stress is
associated with cardiovascular disease.24 In addition,
there is increasing evidence suggesting that oxidative
stress and inflammation in the vessel wall also plays
an important role in the development of restenosis
after angioplasty.2,25 Thrombosis, VSMC migration
and proliferation contribute to restenosis after vascu-
lar injury.26 Several studies strongly suggest that ROS
mediate the proliferative phenotype in VSMC.27
Thrombin-stimulated VSMC migration is associatedTable 3. Plasma levels of Thioredoxin (Trx) before and after angiop
angiography after 6 months
Trx, ng/ml Before 1 h
No restenosis 1.2 (0.5–3.6) 1.0 (0.5–3.0)
Restenosis 0.8 (0.5–1.6) 1.1 (0.5–1.4)
Values are mean and ranges.
* pZ0.12 vs. restenosis at 4 h.
Eur J Vasc Endovasc Surg Vol 29, March 2005with increased generation of ROS, activation of
mitogen-activated protein kinases, production of
growth factors, and chemoattractants.28 Thrombin
stimulates H2O2 and superoxide production in
VSMC. Suppression of these ROS by treatment with
catalase or superoxide dismutase inhibits thrombin-
induced mitogenesis.29 PDGF has been reported to
regulate SMC proliferation via H2O2, and this effect is
attenuated by antioxidants.30
The role of Trx and Grx after angioplasty in patients
with peripheral artery disease has never been assessed
before. However, several studies support the idea that
Trx could play a major role in the development of
atherosclerosis and in the pathology of reperfusion
injury. In human aortic SMC, adenoviral gene transfer
of Trx enhanced Trx enzyme activity and significantly
increased DNA synthesis, suggesting a role for Trx in
SMC proliferation.31 In addition, Trx is upregulated in
atherosclerotic plaques13 and although Trx is mainly a
cytoplasmic protein it can be secreted via a leaderless
pathway.32 Secretion of Trx is stimulated by a wide
variety of stimulus, all having in common that they
induce an oxidative burst in the cell. Thus, oxygen and
H2O2 induce secretion of Trx from cells, including
endothelial cells.33,34 Ischemic-reperfusion injury is a
crucial problem after revascularization. ROS play a
major role in the pathology in reperfusion injury and
several studies have found that Trx has a protective
role in this scenario. Trx has been showed to lower
levels of ROS, like singlet oxygen and superoxide
anion.35 In animal models exposed to reperfusion
injury, treatment with Trx gave higher arterial oxygen
tension and no histological signs of reperfusion
injury.16–18
Plasma levels of Trx in healthy individuals have
been reported to 30 ng/ml.21 Trx levels in this studylasty in patients with and without restenosis at follow-up with
4 h 24 h 1 week
3.4 (0.5–14)* 1.0 (0.5–1.5) 0.8 (0.5–1.8)
1.2 (0.5–1.8) 0.7 (0.5–1.3) 0.8 (0.5–1.3)
Thioredoxin After Angioplasty 285were about 10-fold lower. However, plasma Trx levels
in patients with peripheral arterial disease have never
been measured before. We have previously seen that
patients with neurological disease can have low Trx
levels (3–6 ng/ml) (unpublished data). We cannot
explain why the values of Trx and Grx in the control
group had a tendency to be higher compared to the
PTA group. It could be an expression of a more severe
arterial disease in the PTA group.
We observed that it could exist a correlation
between plasma levels of Trx and development of
restenosis. Patients with elevated plasma levels of Trx
after angioplasty could develop restenosis to a lesser
extent after 6 months compared to patients with
unchanged plasma Trx level. This observation must
be interpreted very cautiously due to low patient
numbers and no multi-variant analysis. A protective
role of Trx in development of restenosis could be
explained by the antioxidative effect of Trx but also by
the effect of Trx in modulating the inflammatory
response after vascular injury. Trx is a chemoattractant
for neutrophils, monocytes and T cells.36 Elevated Trx
in atheriosclerotic lesions enhance inflammation.13 In
contrast, Nakamura et al. showed that increased
plasma Trx impairs the chemotactic responses to
local sites of inflammation.15,37 The peak of plasma
Trx after PTA could inhibit the migration of monocytes
to the lesion. This lead to decreased inflammation
which could result in decreased restenosis.
Although, Grx has some overlapping functions
with Trx, we did not find a similar pattern of Grx
levels in plasma after angioplasty. This supports the
notion that increase of Trx after angioplasty and
reperfusion is specific for Trx, and not a general
increase of proteins involved in the pathology in
oxidative stress. The sources of Trx and Grx after
vascular injury are not clearly defined. Human Trx
was first detected in platelets which is a rich source of
Trx.38 Trx is enhanced in endothelial cells and
macrophages in atherosclerotic plaques from human
carotid arteries.13 In balloon injured rat carotid arteries
Trx immunoreactivity begins to increase from 2 weeks
after injury and is upregulated until 6 weeks in the
neointimal endothelium.13 In human coronary arteries
Grx and Trx are expressed in endothelial cells,
fibroblasts in the adventitia, and most intensely in
medial VSMC.39
Our observations give support to the idea of Trx
playing a role after vascular and reperfusion injury.
The role in the pathology of restenosis needs to be
further evaluated. A study of the effect of infused
recombinant Trx, lowering inflammation at the site of
injury, on restenosis is underway. In animal models
treatment with a variety of antioxidants have reducedneointimal proliferation and promoted vessel remo-
delling.40,41 In clinical trials the antioxidant and lipid-
lowering drug probucol has shown promising results
in preventing restenosis after coronary-artery balloon
angioplasty.42 However, there is a need in future
studies of new markers to assess the degree of
oxidative stress and to monitor the effect of antiox-
idant therapy. Our findings suggest that Trx could play
that role. We conclude that Trx has promising qualities
both as a marker of oxidative stress and as a
therapeutic agent.Acknowledgements
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